NEW TREATMENT APPROVED FOR SICKLE CELL! We are delighted that NICE has today approved the groundbreaking gene therapy, Exa-cel, or Casgevy, for use through the NHS in people living with sickle cell disorder. Our CEO John James OBE comments here.
Today, a plaque honouring the lifesaving work of the UK’s first sickle cell nurse specialist, Professor Dame Elizabeth Anionwu, was unveiled at London’s newest blood donor centre in the heart of Brixton.
Book your appointment to donate blood today: https://t.co/vwsFtx2Dsv
VOXELOTOR WITHDRAWN FROM NHS. We are deeply shocked and extremely disappointed by Pfizer’s sudden decision to withdraw Voxelotor (OXBRYTA®) from the NHS in the UK, and across the world. We were given no warning. Read our full statement here https://t.co/UisEb60s8X
Fantastic news for people living with transfusion dependent thalassaemia!
We await further news of NICE's separate decision on sickle cell. For up to date information about the ongoing SCD appraisal, we have an FAQ sheet https://t.co/mlEjb14Y54
In the Supacell universe + in our universe, you are a superhero @Simply_Sayo ❤️
A powerful discussion between #Supacell creator @RealRapman and poet @Simply_Sayo on the reality of sickle cell disorder and how it disproportionately affects people from Black African and Caribbean backgrounds.
For more information follow @SickleCellUK.
Did you know? Sickle cell disorder is the fastest-growing genetic condition in the UK, affecting around 17,500 people. It causes red blood cells to become sickle-shaped, blocking blood flow, leading to severe pain . More on our website https://t.co/faY1N2kfOk
#WorldSickleCellDay
We're thrilled to announce the approval of Voxelotor (Oxbryta) by The Scottish Medicines Consortium for individuals with sickle cell in Scotland. Thank you for everyone's efforts in achieving this milestone. More information in the bio. #SickleCellAwareness#NewTreatment.
Thousands of sickle cell patients have been given a new treatment lifeline by the NHS from today, following the approval of a new drug for the disease.
This innovative treatment could help up to 4,000 people with sickle cell disease. https://t.co/bee7kg0HqN
We are profoundly grateful this day has arrived. NICE’s (National Institute for Health and Care Excellence) final draft guidance published today, Friday 3 May 2024, recommends Voxelotor (also called Oxbryta).
https://t.co/WjbuMIXLnC
Sickle cell patients ‘let down’ by decision to not approve new gene therapy on NHS
@SickleCellUK@AnthonyNolan @RedCellsrus @redcellemma @AbiWinning
https://t.co/cwv2WTMNhc
Spoke to a Black pharmacist who is feeling suicidal due to bullying from Chief pharmacist. I had similar experience once & knowing that nothing changes in our profession is frustrating. Racism in pharmacy is real!! We need actions & accountability @TheGPhC@PharmaSupport@rpharms
NICE requests more evidence from Pfizer on its sickle cell disease treatment voxelotor, having initially rejected the treatment for #NHS use
https://t.co/rHLfigWCQ3
We’re delighted that @imperialcollege is leading our latest project to understand inequalities in the care of sickle cell disease patients across England, by comparing their care with other rare conditions. Here is the link to their new project blog page: https://t.co/DCVojxP3bE
Atul is one of the community pharmacists who are making it easier for millions of people to get healthcare on the high street.
You can now go to a pharmacy for advice and treatment for seven common conditions and your pharmacist can prescribe medication if you need it.
Yesterday, @JanetDaby MP urged the Govt to prioritise swift pain relief for sickle cell patients at A&E.
The Minister agreed meet with Janet and The Sickle Cell Society to discuss actions.
Contains Parliamentary information licensed under the Open Parliament Licence v3.0
World-first NHS test at Whittington Health🌟
Last night ITV featured our patients and staff in a world-first test which could help reduce the risk of side effects from blood transfusions.🩸
@SickleCellUK@teamukts@NHSEngland
https://t.co/VokoU8hCs6
Thousands of patients with inherited blood disorders are to get a world-first NHS test to curb transfusion side effects, reducing the risk of side effects and offering more personalised care.
Read more here ➡️ https://t.co/lObDRb0XjZ
Despite established guidelines, many individuals with Sickle Cell Disease face barriers to quality care.
In their editorial, Jacob and Yui propose the following mechanisms to improve Sickle Cell Care (summarised below) 👇
https://t.co/5GQMeyQRQe